WARREN, N.J., Feb. 2, 2026 — Aquestive Therapeutics announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of Anaphylm, an investigational sublingual epinephrine film intended for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or more. The FDA’s feedback, issued on January 30, 2026, identified deficiencies limited primarily to human factors, packaging, and administration, while noting no concerns related to chemistry, manufacturing, and controls (CMC).
Science Significance
Anaphylm represents a novel, non-invasive epinephrine delivery platform, designed to address long-standing challenges associated with injectable auto-injectors, including ease of use, portability, and rapid administration. Delivered as a polymer-based sublingual film, Anaphylm dissolves quickly without the need for water or swallowing, offering potential advantages in emergency settings. The FDA’s CRL does not question the pharmacokinetic comparability of Anaphylm to approved epinephrine auto-injectors, nor its overall safety profile, which was supported by a comprehensive clinical development program spanning 11 studies and nearly 1,000 administrations. Scientifically, the remaining gaps relate not to drug performance, but to user interaction under high-stress conditions, a critical consideration for life-saving therapies.
Regulatory Significance
From a cGxP perspective, the CRL highlights the FDA’s heightened focus on human factors validation for emergency-use products. The agency cited issues related to pouch opening and film placement, which could pose safety risks if not addressed during an anaphylactic event. Importantly, the FDA confirmed that no CMC deficiencies were identified, and that required human factors and pharmacokinetic (PK) studies may be conducted in parallel. Aquestive plans to request a Type A meeting with the FDA and has indicated that, pending successful completion of the requested studies, it expects to resubmit the NDA as early as Q3 2026, positioning this as a remediable regulatory delay rather than a fundamental setback.
Business Significance
Advertisement
While the CRL delays U.S. approval, Aquestive remains well-capitalized and has reiterated its confidence in Anaphylm’s commercial potential. The company continues to advance global regulatory strategies, with plans to submit applications in Canada and the European Union by the end of 2026. Notably, the European Medicines Agency (EMA) has indicated that no additional clinical trials are required prior to submission. From a business standpoint, resolving human factors concerns may ultimately strengthen product differentiation and market acceptance, particularly in a crowded epinephrine market where usability is a key competitive factor.
Patients’ Significance
For patients and caregivers, the FDA’s decision underscores the importance of safe and intuitive drug administration during medical emergencies. Anaphylaxis remains under-treated, with documented underuse of epinephrine due in part to fear of injection or device complexity. Anaphylm’s oral, needle-free format has the potential to lower barriers to timely treatment, provided usability concerns are fully addressed. The FDA’s emphasis on human factors ultimately serves to protect patients by ensuring that innovative delivery technologies perform reliably under real-world conditions.
Policy Significance
The CRL reflects broader regulatory policy trends emphasizing patient-centric design and real-world usability, particularly for emergency therapeutics. FDA scrutiny of labeling, instructions for use, and packaging aligns with evolving expectations that drug safety extends beyond molecular efficacy to include user interaction and administration context. This case may inform future regulatory guidance for non-traditional drug delivery systems, reinforcing the role of human factors engineering within the GxP framework.
The FDA’s Complete Response Letter for Anaphylm highlights the critical intersection of innovation, usability, and regulatory rigor in modern drug development. While additional work is required, the absence of CMC concerns and the clarity of FDA feedback provide a defined path forward for Aquestive Therapeutics. As the company prepares for resubmission, Anaphylm remains a compelling example of how pharma innovation guided by GxP principles can evolve toward safer, more accessible treatments for life-threatening conditions.
Source: Aquestive Therapeutics press release
